Affiliation:
1. Respiratory, The 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Lanzhou, Gansu Province, China
2. Respiratory, The Clinical Medical College of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Abstract
Introduction:
Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-1 immunosuppressant, had a positive effect on BCC.
Patient concerns:
A 74-year-old male patient presented with a mass in the left back in October 2021, which was surgically removed and diagnosed as BCC. The patient was diagnosed with squamous lung cancer after presenting with a cough and coughing up a small amount of white, sticky sputum in December 2021.
Diagnosis:
BCC and squamous lung cancer.
Interventions:
Docetaxel + nedaplatin systemic chemotherapy combined with tislelizumab immunotherapy.
Outcomes:
Both BCC and squamous lung cancer were significantly reduced in size.
Conclusion:
After 2 cycles of immunotherapy with tislelizumab, the lung tumor shrank, the back mass disappeared, and the wound healed.
Publisher
Ovid Technologies (Wolters Kluwer Health)